在刚果有和没有痴呆症的个人中,阿尔茨海默病血生物标志物的初步参考值

在刚果有和没有痴呆症的个人中,阿尔茨海默病血生物标志物的初步参考值

相关实验视频

Updated: Jun 5, 2025

Absolute Quantification of Aβ1-42 in CSF Using a Mass Spectrometric Reference Measurement Procedure

08:40

Absolute Quantification of Aβ_1-42 in CSF Using a Mass Spectrometric Reference Measurement Procedure

Published on: March 21, 2017

7.5K

Jean Ikanga^1,2, Kharine Jean¹, Priscilla Medina³

¹Department of Rehabilitation Medicine, Emory University School of Medicine, Atlanta, GA, United States.

Frontiers in aging neuroscience

|December 6, 2024

概括

这项研究确定了刚果成年人阿尔茨海默病 (AD) 血生物标志物的初步参考值,有助于撒哈拉以南非洲地区的痴呆症诊断.

科学领域:

神经学神经学
生物标志物发现发现
公共卫生公共卫生

背景情况:

对阿尔茨海默病 (AD) 血生物标志物的参考值 (RV) 已在西方国家建立,但在撒哈拉以南非洲人口中缺乏.
这种差距阻碍了不同种族群体中精确的痴呆症诊断和管理.

研究的目的:

在刚果成年人中确定AD和其他血生物标志物的初步参考值 (RV).
评估这些生物标志物的实用性,以区分痴呆状态.

主要方法:

在使用SIMOA的85名刚果成年人中分析了包括粉样蛋白-β (Aβ42/40),酸化 (p-tau181,p-tau217) 在内的血生物标志物,神经丝光 (Nfl),质纤维酸蛋白 (GFAP) 和炎症标志物 (IL-1b,IL-10,TNFα).
采用线性和逻辑回归来评估根据年龄,性别和神经状态的生物标志物差异,以及用于痴呆症预测.

主要成果:

为Aβ42/40,p-tau181,p-tau217,Nfl,GFAP,TNFα,IL-1b和IL-10建立了初步的RV.
酸化-217 (p-tau217),GFAP和Nfl显示出对痴呆的最高预测准确度,AUC从0.72到0.73.7不等.
生物标志物度通常没有根据年龄或性别有显著差异,除了p-tau181和GFAP.

结论:

这项研究为撒哈拉以南非洲人口中与痴呆相关的血生物标志物提供了关键的初步参考值.
这些发现可以支持对刚果成年人的查,临床诊断判断和痴呆症的分类.
建立特定人口的RV对于全球公平,准确的神经疾病管理至关重要.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.刚果刚果刚果刚果刚果生物标志物生物标志物痴呆症痴呆症是一种痴呆症.参考值是指指标值的参考值.

更多相关视频

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

7.8K

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

32.2K

相关概念视频

01:26

Alzheimer's Disease: Overview

447

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

447

01:30

Dementia

96

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....